zomato share price: what foreign brokers in Zomato, Tata Motors, Sobha and 7 said.

New Delhi: Brokerages like JPMorgan and Citi have maintained their positive position on Zomato; CLSA retains the purchase on () and upgrades to ‘Outperform’ for favorable risk-reward. BofA Securities maintained its neutral position, while Morgan Stanley began coverage of the chemical space, including three stocks.

JPMorgan says consistent Ebitda losses continue to decline

And with the return of the order, that Gross Order Value (GOV) has increased strongly. It said food supply earnings for Zomato rose again in the March quarter, as it suggested a price target of 130 130 on the stock.

Citi’s stock has a target price of Rs 80 to include FY22 numbers It also reported a 6 per cent hike in GOV and a consistent Ebitda loss of Rs 220 crore.

Morgan Stanley has started coverage in SRF with overweight position with a target of Rs 2,757. Start coverage on it

(Target Rs 954) and (Rs 4,562). Initiating coverage in the chemical sector, Morgan Stanley said the future of India’s specialty chemicals would look very different and the market was not setting prices at 200-600 basis points in exchange for equity expansion.

CLSA has upgraded three auto stocks because it thinks companies could benefit from falling steel prices, widening margins and a recovery after Covid-19.

What foreign brokers say in Zomato,

Shobha and 7 other stocks’.

The brokerage, meanwhile, has maintained its purchase at HAL with a target price of Rs 1,930 as FY24’s earnings assessment is 15 times cheaper. Towards the end of FY22, the PAT rose 17 percent, leading to a change in the balance sheet, foreign brokerages reported.

The same brokerage has upgraded Sobha to outperform with a target price of Rs 805 as it feels that the risk-reward is now favorable after the sharp fall in the stock. It slashed its presale estimate for FY23-FY24 by 13 percent and called the FY23 guidelines conservative.

BOFA Securities has remained neutral in Davis Labs with a target of Rs 4,300 crore as the risk of core earnings is running out. Custom synthesis drives revenue beat but the generic API remains weak, it says.

(Disclaimer: The recommendations, suggestions, opinions and opinions offered by the experts are their own. These do not represent the views of the Economic Times)

Related Posts

Leave a Reply

Your email address will not be published.